Emmes Appoints Peter Ronco as Chief Executive Officer
Emmes has announced that Peter Ronco has been named CEO, effective immediately.
Ronco succeeds Christine Dingivan, who will serve as a senior advisor to Executive Chairman Sastry Chilukuri and Emmes’ board of directors.
“Emmes has a 45-year legacy of scientific innovation and advancing public health. Peter’s leadership and operational expertise in the life sciences sector will be invaluable in our next phase of growth. I am excited to welcome Peter to the Emmes team,” said Kyle Peterson, managing director at New Mountain Capital and member of the board of the directors of Emmes, in a press release. “We are grateful for Christine’s leadership through an important chapter of growth and diversification after taking over from the original founders. She is a remarkable physician-entrepreneur and industry leader and will continue to support Peter, Sastry, and the board going forward.”
“Peter is a seasoned and innovative life sciences leader. He brings deep experience in running global operations with frontline use of technology and data science, which will propel our company forward,” added Chilukuri in a press release.
Ronco is a global pharmaceutical executive with experience in a number of R&D leadership positions over more than two decades. He most recently served as senior vice president, global development at Johnson & Johnson, responsible for the design and delivery of a drug development portfolio of more than 500 active clinical studies across all therapeutic areas and phases of development. He has also held senior roles with Bristol Myers Squibb, Accenture, and Pfizer.
“I am thrilled to be joining a company with an outstanding scientific track record and extensive credibility in clinical research,” said Ronco in a press release. “Emmes has a storied history, addressing some of the most complex health issues of our time. We look forward to an exciting future together as we partner with patients, clinical sites, government agencies, and biopharmaceutical companies to advance the next phases of scientific innovation and change the trajectory of health care.
“I believe that advances in decentralized clinical trials, data science, and generative AI offer huge potential to make clinical research even faster and more patient-focused. Embracing and accelerating the uptake of these approaches will allow us to have a greater impact on global health and biopharma innovation in the discovery and development of new medicines.”
Ronco is a graduate of Nottingham University in the UK and will be based out of Emmes’ Rockville, Maryland, headquarters.
Reference
Emmes Appoints Peter Ronco as Chief Executive Officer. (2023, October 2). Emmes.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
